Development of novel agents for the treatment of early estrogen receptor positive breast cancer. (March 2022)

• Record Type: Journal Article
• Authors: Elliott, Mitchell J.; Cescon, David W.
• Is Part Of: Breast. Volume 62(2022)Supplement 1
• Page Start: S34
• Page End: S42
• Publication Date: 2022-03
• Subjects: Breast cancer -- Adjuvant therapy -- Endocrine therapy -- Targeted agents -- Estrogen receptor -- mTOR -- PI3K -- SERD -- AKT -- Early breast cancer -- PARP inhibitor; Breast -- Diseases -- Periodicals; Breast -- Tumors -- Periodicals; Breast -- Periodicals; Electronic journals; Periodicals; 616
• DOI: 10.1016/j.breast.2021.11.007
• Languages: English
• ISSNs: 0960-9776

Abstract

Abstract: Estrogen receptor (ER+) breast cancer is the most frequently diagnosed breast cancer subtype. Currently, adjuvant treatment for early stage disease consists of endocrine therapy, with or without chemotherapy and bone-targeted therapy, delivered in a risk-adapted manner. Despite this multimodal approach, a significant proportion of high risk patients will develop incurable distant recurrences. There is an ongoing need to develop new treatment strategies that address the biologic causes of treatment failure and to identify the individual patients who can benefit from such interventions. Here we review the clinical investigation of targeted and novel therapies, including inhibitors of the PI3K-AKT-mTOR pathway, oral selective estrogen receptor degraders (SERDs), and PARP-inhibitors for the treatment of early ER+ breast cancer. Furthermore, we highlight opportunities in biomarker development to help guide the delivery of escalated adjuvant strategies.